NDTV Profit (IN)
Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery
Jubilant Pharmova's revenue growth remains healthy during the quarter, but earnings are being held back by the SPECT supply gap and Montreal remediation costs, says Nirmal Bang.